There were 720 press releases posted in the last 24 hours and 169,288 in the last 365 days.

H1 2016 Sales: +7% to EUR 8.9m

Strong Growth in Key Direct Markets: United States, China, France; Strategy: Emphasis on Liver and Breast Markets; Double Digit Growth in Services Sales: +23%


/EINPresswire.com/ -- AIX-EN-PROVENCE, FRANCE -- (Marketwired) -- 07/19/16 -- SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814, PEA-PME eligible), the highly-innovative ultrasound company, today announces its revenue for the 1st half of 2016.


In thousands of euros                    2016      2015 Change (%)
Products                                3,429     2,861        +20%
Services                                  474       371        +28%
Q1 sales                                3,903     3,232        +21%
Products                                4,434     4,579         -3%
Services                                  522       440        +18%
Q2 sales                                4,956     5,019         -1%
Products                                7,863     7,440         +6%
Services                                  996       811        +23%
H1 sales                                8,859     8,251         +7%
Other revenue*                            561       491        +14%
Total H1 revenue                        9,420     8,742         +8%

Unaudited data
Note (*): this revenue is non-recurrent by nature and is not part
of the Group's core business.

Supersonic Imagine's sales for the 1st half of 2016 was EUR 8.9m, a growth of +7% compared with H1 2015 (EUR 8.3m). At constant currency, growth was +7% between these two periods.

Over the first half of the year, SuperSonic Imagine confirmed the upturn in its priority markets, the United States, France and China, with growth rates of +50% (direct sales), +47% and +12% respectively. These three markets accounted for 67% of total sales over the first six months of 2016 (vs. 62% in H1 2015). Service sales increased by +23% and now accounts for 11% of total sales compared to 10% the same period last year.

Q2 2016 saw a slight decline in sales of -1% to EUR 5.0m (0% at constant currency), following a 1st quarter of 2016 that saw sales grow by +21% to EUR 3.9m (vs. EUR 3.2m, +19% at constant currency). This Q2 decline vs. Q2 2015 was primarily due to a decrease in Asia (excluding China) and in Europe (excluding France). Over the same period, China recorded a +19% increase in sales and accounted for 29% of total sales versus 24% a year earlier. In the United States, the growth was due to the Company's direct sales team primarily in the Breast and Liver space. In Europe, France also recorded a good first half thanks to the performance of its direct sales network.

Elisabeth Winter, SuperSonic Imagine's Finance Director, says: "We are pursuing our focus on the main growth areas in terms of regions and applications, following a strong first quarter. At the same time, we are continuing to implement tighter cost controls in response to the mixed growth rates recorded over the first half of the year."

Other revenue essentially comes from access to the Group's technology. This non-recurrent revenue is not written down as sales, insofar as it is not part of its core activity.

Next press financial release: H1 2016 results will be published on September 12, 2016

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S - Planewave UltraSensitive™ Imaging.

ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging.

SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

Contact information:

SuperSonic Imagine
Bernard Doorenbos
CEO
Email Contact
+33 6 15 66 64 68

NewCap
Investor Relations - EU
Pierre Laurent / Florent Alba
Email Contact
+33 1 44 71 98 55

SuperSonic Imagine
Elisabeth Winter
Finance Director, Executive VP
Email Contact
+33 6 61 45 69 17

Pascale Communication
Media Relations - US
Amy Phillips
Email Contact
+1 412 327 9499